Cocoon Bioscience

Cocoon Bioscience is a private, Madrid-based biotech leveraging a proprietary insect-based expression system, CrisBio®, for recombinant protein production. The platform uses Trichoplusia ni pupae as natural bioreactors, offering advantages in cost, scalability, and the ability to produce complex proteins with proper folding and post-translational modifications. While currently focused on providing enzymes and custom development services, the technology presents a significant platform opportunity for biologics manufacturing across life sciences, positioning the company as an innovative CDMO-like player in the biologics and microbiome sectors.

CrisBio®: An automated recombinant protein expression platform that uses insect chrysalises (Trichoplusia ni pupae) as natural bioreactors, leveraging the Baculovirus Expression Vector System (BEVS) for production of complex proteins with eukaryotic post-translational modifications.

Cocoon competes with large, established CDMOs using CHO, E. coli, and yeast systems, as well as other novel platform companies (e.g., plant-based, algal). Its differentiation lies in the unique insect bioreactor approach, promising lower costs and inherent scalability for complex proteins, but it must overcome the inertia of validated, industry-standard platforms.